Biotech | February 26, 2026
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Subscribe To Our Newsletter & Stay Updated
